Table 1.

Patient characteristics

Characteristic
Age, years
 Median (range)55 (25–78)
Race
 White13 (50%)
 Black11 (42.3%)
 Asian1 (3.8%)
 Other1 (3.8%)
ECOG
 012 (46.2%)
 111 (42.3%)
 23 (11.5%)
BRCA status (germline)
 BRCA1/2 positive1 (3.8%)
 BRCA negative15 (57.7%)
 Unknown/not done10 (38.5%)
Prior (neo)adjuvant chemotherapy
 Yes24
  Anthracycline and taxane based16
  Anthracycline based2
  Taxane based5
  Other/unspecified2
 No2
Prior (neo)adjuvant hormonal therapya5
Other1
Number of prior systemic therapy for metastatic disease
 All regimens, median (range)1.5 (0–4)
 Chemotherapy1 (0–4)
 Hormonala1.5 (1–2)
 Other/unknown1 clinical trial
1 PDL-1 trial
AR status (N = 21)
 Positive5 (23.8%)
 Negative16 (76.2%)
  • aEligible patients could have previously had ER-positive and/or HER2-positive disease, but must have had confirmation of TNBC on their most recent tissue biopsy.